Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Apr;19(4):581-7.
doi: 10.1007/s00198-007-0483-0. Epub 2007 Oct 9.

The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study

A Papaioannou  1 , C C Kennedy, G Ioannidis, Y Gao, A M Sawka, D Goltzman, A Tenenhouse, L Pickard, W P Olszynski, K S Davison, S Kaiser, R G Josse, N Kreiger, D A Hanley, J C Prior, J P Brown, T Anastassiades, J D Adachi; CaMos Research Group
Affiliations
Randomized Controlled Trial

The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study

A Papaioannou et al. Osteoporos Int. 2008 Apr.

Abstract

We examined osteoporosis diagnosis/treatment in 2,187 community dwelling men age 50+. After five years in the study, 90% of men with fragility fractures remained undiagnosed and untreated for osteoporosis. The need to treat fragility fractures is well established in guidelines, and these numbers represent an important care gap.

Introduction: Whether physicians in the community are recognizing and appropriately treating osteoporosis and fragility fractures in men remains unknown. We examined the rate of diagnosis and treatment in community dwelling men participating in the Canadian Multicentre Osteoporosis Study (CaMos).

Methods: Between February 1996 and September 2002, 2,187 participants were recruited from nine sites across Canada and prospectively followed. Information on osteoporosis diagnosis, fractures, medications were collected annually by a detailed questionnaire. DXA examination of lumbar spine (L1-4) and hip were conducted at baseline and year five.

Results: Diagnosis and treatment in men with clinical fragility fractures was low: at baseline and year five only 2.3% and 10.3% of men with a clinical fracture reported an osteoporosis diagnosis, respectively. At year five, 90% of men with a clinical fragility fracture were untreated. Hip fractures were the most commonly treated (37.5% by year five). A diagnosis of osteoporosis resulted in greater treatment: 67% of participants with diagnosed osteoporosis were treated with a bisphosphonate and 87% were taking calcium and/or vitamin D (year five).

Conclusions: In this population-based study, both a diagnostic and therapeutic gap existed between knowledge and practice related to fragility fractures and osteoporosis in men aged >or=50 years.

PubMed Disclaimer

Conflict of interest statement

Alexandra Papaioannou, MD, MSc Consulting Role: Amgen, Eli Lilly, Merck Frosst, Novartis, Proctor & Gamble, sanofi aventis Clinical Trials: Eli Lilly, Merck, Novartis, Proctor & Gamble, sanofi-aventis, Wojciech P. Olszynski, MD, PhD Consulting Role: Abbott Laboratories, Merck Frosst, Amgen, Novartis, Aventis, Pfizer, Boehringer Ingelheim, Procter & Gamble, Eli Lilly, Sanofi-Synthelabo, Genzyme, Schering Canada, GlaxoSmithKline, Solvay Pharma, Hoffmann-LaRoche, Wyeth, Janssen-Ortho Inc./Ortho-Biotech STEPHANIE KAISER, MD Consulting Role: Eli Lilly, Proctor & Gamble/Aventis, Merck, Servier, Novartis, Astra Zeneca, Abbott Advisory boards: Eli Lilly, Novartis, Servier David A. Hanley, MD Advisory Boards: Merck, Proctor & Gamble, Eli Lilly, Novartis, NPS Pharmaceuticals, Paladin Clinical Trials: Merck, Proctor & Gamble, Eli Lilly, Novartis, NPS Pharmaceuticals, Pfizer, Amgen, Wyeth-Ayerst, Roche Jonathan D. Adachi, MD Consulting Role: Amgen; Astra Zeneca, Eli Lilly; GlaxoSmithKline; Merck Frosst; Novartis; Proctor & Gamble; Roche; Sanofi Aventis; Servier Clinical Trials: Eli Lilly; GlaxoSmithKline; Merck; Novartis; Pfizer; Proctor & Gamble; sanofi-aventis; Servier; Wyeth-Ayerst David Goltzman, MD Consulting Role: Lilly, Novartis, Merck, sanofi-aventis, Proctor & Gamble, Servier Robert G. Josse, MD Advisory boards, honoraria, research grants: Lilly, Proctor & Gamble/sanofi-aventis, Merck, Novartis, Servier, GlaxoSmithKline, Amgen Jacques P. Brown, MD Consulting Role: Eli Lilly, Novartis, Procter & Gamble, and Sanofi-Aventis Jerilynn C. Prior MD, Courtney C. Kennedy MSc, George Ioannidis MSc, Yongjun Gao MSc, Anna M. Sawka MD, PhD, Nancy Kreiger PhD, Shawn Davison PhD, Laura Pickard MA: No competing interests to declare.

Figures

Fig. 1
Fig. 1
a: CaMos DXA status of men reporting an osteoporosis diagnosis at baseline b: CaMos DXA status of men reporting an osteoporosis diagnosis at year five
Fig. 2
Fig. 2
Percentage of men with clinical fragility fracture(s)* taking bisphosphonates
Fig. 3
Fig. 3
Percentage of men reporting an osteoporosis diagnosis* taking bisphosphonates, calcium/vitamin D *Total number of men with an osteoporosis diagnosis: N=24 at baseline and N=125 at year five.
See this image and copyright information in PMC

References

    1. National Osteoporosis Foundation. America’s bone health: the state of osteoporosis and bone health. National Osteoporosis Foundation; Washington, DC. USA: 2002.
    1. Cooper C, Campion G, Melton LJ., 3rd Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2:285–289. - PubMed
    1. Pluijm SM, Tromp AM, Smit JH, et al. Consequences of vertebral deformities in older men and women. J Bone Miner Res. 2000;15:1564–1572. - PubMed
    1. Burger H, Van Daele PL, Grashuis K, et al. Vertebral deformities and functional impairment in men and women. J Bone Miner Res. 1997;12:152–157. - PubMed
    1. Jackson SA, Tenenhouse A, Robertson L. Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos) Osteoporos Int. 2000;11:680–687. - PubMed

Publication types

Grants and funding